drugset / Trial / NCT00444379
Anti-Retrovirals for Kaposi's Sarcoma
Phase 4
Completed
224 enrolled
University of California, San Francisco
Abbott · collabGilead Sciences · collabMerck Sharp & Dohme LLC · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The primary purpose of this study is to determine whether a protease inhibitor-based antiretroviral regimen is more efficacious than a non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimen in promoting the regression of KS tumor burden in persons with AIDS-related KS in Africa.
Timeline
- Start
- 2007-04
- Primary completion
- 2012-02
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Efavirenz | Other / unclassified | 600 mg | — |
| Comparator | Lopinavir | Other / unclassified | 200 mg | — |
| Comparator | Ritonavir | Other / unclassified | 50 mg | — |
| Comparator | Tenofovir | Small molecule | 300 mg | — |
| Comparator | emtricitabine | Other / unclassified | 200 mg | — |